AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 80(4), 2009, pp. 583-587
Copyright © 2009 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Béraud, G.
Right arrow Articles by Cabié, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Béraud, G.
Right arrow Articles by Cabié, A.

Cotrimoxazole for Treatment of Cerebral Toxoplasmosis: An Observational Cohort Study during 1994–2006

Guillaume Béraud, Sandrine Pierre-François, Adeline Foltzer, Sylvie Abel, Bernard Liautaud, Didier Smadja, AND André Cabié*
Infectious Diseases Department Comité de Coordination de la Lutte Contre le Virus de l’Immunodéficience Humaine de la Martinique, Neurology Department, Centre d’Investigation Clinique-Epidémiologique Clinique Antilles Guyane (INSERM CIC-EC 802), University Hospital of Fort-de-France, Fort de France, Martinique, France

Cotrimoxazole (trimethoprim/sulfamethoxazole [TMP-SMX]) is an alternative treatment for toxoplasmic encephalitis because it is inexpensive, well-tolerated, and as effective as pyrimethamine-sulfadiazine, which is the first-line drug regimen). We report results of a large cohort study of patients with acquired immunodeficiency syndrome who were treated for toxoplasmic encephalitis with cotrimoxazole. The mean follow-up period was more than three years. Our results confirm that cotrimoxazole is effective (85.5%), with a relatively low incidence of side effects (22%; 7.4% requiring treatment interruption). Relapse occurred in 30.1% of the patients at a mean ± SD of 7.8 ± 16.2 months after the first episode. The only risk factor for relapse was poor treatment and/or prophylaxis adherence. Mortality was significantly higher (P < 0.05) before 1996 than after 1996 (the era of highly active antiretroviral therapy). There was a non-significant trend towards a higher rate of relapse among patients treated before 1996 (P = 0.06). Consequently, cotrimoxazole could be a first-line drug regimen for curative treatment and prophylaxis of toxoplasmic encephalitis.

Received April 3, 2008. Accepted for publication December 29, 2008.

Acknowledgment: We thank David D. Young for substantive help in editing the manuscript.

* Address correspondence to André Cabié, Infectious Disease Department, University Hospital of Fort de France La Meynard, BP 632 97261, Fort de France, Martinique, France. E-mail: andre.cabie{at}chu-fortdefrance.fr

Authors’ addresses: Guillaume Béraud, Sandrine Pierre-François, Adeline Foltzer, Sylvie Abel, Bernard Liautaud, and André Cabié, Infectious Diseases Department, University Hospital of Fort de France, BP 632 97261, Fort de France cedex, Martinique, France, E-mail: andre.cabie{at}chu-fortdefrance.fr. Didier Smadja, Neurology Department, University Hospital of Fort de France, BP 632 97261 Fort de France cedex, Martinique, France.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society of Tropical Medicine and Hygiene.